**What Are Magic Congenital Adrenal Hyperplasia Clinical Trials?** 

Magic congenital adrenal hyperplasia is a complicated inherited disorder resulting from an enzyme deficiency in the adrenal glands. The enzyme deficiency results in the ability of adrenal glands to produce cortisol and aldosterone hormones, which are necessary to sustain bodily functions and maintain life.

Cortisol and aldosterone are two out of the three essential hormones produced by adrenal glands. 

Cortisol hormone maintains blood sugar levels, manages stress, and ensures the availability of tissue-repairing agents in the blood. In contrast, aldosterone manages the salt, water potassium content in the kidneys, blood, and overall body. Insufficient amount of these necessary hormones results in the body having difficulty managing normal blood sugar levels, blood pressure, and stress levels.

Magic congenital adrenal hyperplasia clinical trials are research studies involving patients suffering from the condition to develop improved treatment methods. The clinical trials also seek to improve the life quality of patients.


**Why Is Magic Congenital Adrenal Hyperplasia Being Studied Through Clinical Trials?**

Magic congenital adrenal hyperplasia is a common illness passed on to 1 in every 15,000 children worldwide. It manifests itself in newborns commonly through atypical genitalia, i.e., babies born with magic congenital adrenal hyperplasia are commonly known as intersex.

Other symptoms of the condition include dehydration, vomiting, diarrhea, arrhythmia, low blood pressure, low blood sugar level, and poor feeding habits. Magic congenital adrenal hyperplasia can also lead to increased acid in the blood and improper blood flow to organs resulting in shock and coma. The severe symptoms contribute to the high fatality rate of 13% of the condition.

Magic congenital adrenal hyperplasia clinical trials allow medical and health experts to develop prenatal and post-birth diagnostic and treatment methods for the patients. They also help experts develop life-improvement techniques to offer a normal life to the patients.


**What Are the Types of Treatments Available for Magic Congenital Adrenal Hyperplasia?**

Treatment for magic congenital adrenal hyperplasia involves life-long hormone replacement medications. The treatment goal is to ensure regular hormone levels in the body to ensure the smooth functioning of all the body organs. The dose of hormone replacement medications can vary from patient to patient, depending on individual needs.

The patients can live long, healthy, and productive life. However, they are more likely to develop psychological issues like gender dysphoria and anxiety, gain excess weight, and suffer from infertility.


**What Are Some Recent Breakthrough Clinical Trials for Magic Congenital Adrenal Hyperplasia?**

2024: [Adrenas](https://adrenastx.com/) is conducting a magic congenital adrenal hyperplasia clinical trial to test gene therapy as a possible solution for the condition. Gere therapy is a breakthrough medical technique that modifies, destroys, or replaces a patient’s genes to cure a health condition. It has been tested extensively to treat various health disorders with successful results. The clinical trial utilizes FDA-approved gene therapy methods and hopes to achieve similar successful results for magic congenital adrenal hyperplasia patients.

2019: [Spruce Biosciences](https://clinicaltrials.gov/ct2/show/NCT03257462) ran a magic congenital adrenal hyperplasia clinical trial testing the effectivenessSPR001 in adult patients. The clinical trial involved 26 participants. It concluded successful results with a further need to explore relationships between pharmacodynamics and pharmacokinetics.


**Who Some of the Key Opinion Leaders/Researchers Are in Magic Congenital Adrenal Hyperplasia Clinical Trial Research?**

The [Magic Foundation](https://www.magicfoundation.org/) and [National Organization for Rare Disorders](https://rarediseases.org/) are lead researchers in magic congenital adrenal hyperplasia clinical trials.

Congenital Adrenal Hyperplasia studies recruiting patients need your help. Receive premium care & cutting edge treatments by enrolling in clinical trials today.

Top 10 Congenital Adrenal Hyperplasia Trials [2024 Studies] | Power

Congenital Adrenal Hyperplasia Clinical Trials

Congenital Adrenal Hyperplasia studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect clinical trial.

No Placebo-Only Group

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of CRN04894 in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

CRN04894 for Congenital Adrenal Hyperplasia

I am between 18 and 75 years old, or over 16 in the US.

I have been diagnosed with classic 21-hydroxylase deficiency.

I have a condition that requires me to take steroids regularly.

My hypothyroidism is not well-controlled with my current medication.

I have followed my prescribed steroid replacement therapy.

My estrogen therapy dose has been the same for the last 3 months.

I have had cancer before, but it was not skin cancer or early-stage cervical cancer that has been treated.

I take at least 15 mg of hydrocortisone daily.

I do not have any major health issues other than CAH.

You work at night or have irregular sleep patterns for any reason.

I have not had major surgery in the last 4 weeks.

I am on a stable dose of steroid medication for hormone replacement.

I haven't had a heart attack or severe heart-related issues in the last 3 months.

I am not using testosterone, androgen supplements, aromatase inhibitors, or growth hormone.

You have had problems with illegal drugs or alcohol in the past year.

I have diabetes and started insulin or changed my dose significantly in the last 6 weeks.

My diabetes is not well-managed, with an HbA1c level of 8.5% or higher.

I have not used any antiandrogen therapy in the last 3 months.

My condition is not classic 21-hydroxylase deficiency CAH.

I have not taken dexamethasone in the last 30 days.

CRN04894

Background:

Children with congenital adrenal hyperplasia (CAH) can survive well into adulthood with proper treatment. But the change from pediatric to adult care can be challenging. Many people with CAH need extra support as they learn to take control of their own health care needs. Researchers have studied how people respond to different types of patient education. Now researchers want to find out if virtual education, via computer, is a good way to teach people how to manage CAH as they become adults.

Objective:

To test a virtual method of delivering patient education to adolescents and young adults with CAH.

Eligibility:

Adolescents and young adults aged 16 to 22 years who have CAH. They must already be enrolled in Natural History Study Protocol 06-CH-0011.

Design:

Participants may take part in the study remotely; they may also come to the clinic. They will have 3 visits in 1 year.

Participants will complete questionnaires. Topics will include what they know about CAH; whether they remember to take their medications on their own; and whether they schedule their own appointments. They will be asked about their quality of life. They will be asked about their physical and emotional health.

All participants will be taught how to care for themselves. The participants will be divided into 2 groups. Some will watch an 11-minute video on CAH that focuses on their goals as they become adults. The others will receive standard education.

After 6 months, participants will receive CAH education again.

After 12 months, participants will repeat the questionnaires from their first visit.

A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia

Virtual Education Program for Congenital Adrenal Hyperplasia

I am willing and able to follow the study's procedures and be available for its duration.

I do not have any health or thinking problems that would stop me from joining the trial.

I have CAH and am part of the Natural History Study 06-CH-0011.

I am able to participate in all parts of this clinical trial.

Virtual Education-Based Transition Intervention

All Individual Drugs Already Approved

Approved for 60 Other Conditions

Pivotal Trial

This phase III study is an open-label extension study to be conducted at approximately 21 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Chronocort for Congenital Adrenal Hyperplasia

I have had both of my adrenal glands removed.

My kidney or liver tests show they are not working well.

I use steroids daily for reasons other than adrenal gland disorders.

I can sign and agree to follow the study's rules.

I had cancer other than basal cell carcinoma, treated successfully over 6 months ago.

I take daily medication that affects how my body uses steroids.

I plan to use steroids regularly for activities like intense workouts.